Silvia Martin Lluesma

Author

SIB Swiss Institute of Bioinformatics ORCID

Also Known As

Martin Lluesma, Silvia, Martin-Lluesma, S., S Martin Lluesma, S. Martin-Lluesma, S. Martín-Lluesma, S.M. Lluesma, Silvia Martin Lluesma, Silvia Martin-Lluesma, Silvia Martin‐Lluesma, Silvia Martín-Lluesma

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

SIB Swiss Institute of Bioinformatics University of Lausanne Ludwig Cancer Research University Hospital of Lausanne

About

Silvia Martin Lluesma is an author at SIB Swiss Institute of Bioinformatics specializing in medicine, cell signaling, and precision vaccinology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	499
2	Natural Sciences	1	1	426
3	Cell Biology	1	1	426
4	Immunology	1	1	73
5	Molecular Biology	1	1	426

Silvia Martin Lluesma

Publications

759

Citations

H-Index

Page 1

	Year	Citations
Role of Hec1 in Spindle Checkpoint Signaling and Kinetochore Recruitment of Mad1/Mad2 Silvia Martin Lluesma, Volker M. Stucke, Erich A. Nigg Science Spindle Checkpoint SignalingMolecular BiologyCell CycleEpigeneticsCell Regulation	2002	426
Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1 Silvia Martin Lluesma, Céline Schaeffer, Eva Isabelle Robert, Hepatology	2008	102
Recombinant Antibodies Against Subcellular Fractions Used to Track Endogenous Golgi Protein Dynamics <i>in Vivo</i> Clément Nizak, Silvia Martin Lluesma, Sandrine Moutel, Traffic	2003	99
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients Michal Bassani‐Sternberg, Antonia Digklia, Florian Huber, Frontiers in Immunology ImmunologyImmunoeditingPathologyImmunotherapeuticsImmune Checkpoint Blockade	2019	73
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma Apostolos Sarivalasis, Caroline Boudousquié, Klara Balint, Journal of Translational Medicine	2019	59

Page 1